用马利兰、环磷酰胺、足叶乙甙为预处理方案对急性髓系白血病患者异基因骨髓移植治疗第一次完全缓解时的高剂量化疗

• 作 者: A.R.Zander C.Berger N.Krger M.Stockschlder W.Krǜger M.Horstmann J.Grimm W.Zeller Hkabisch R.Erttmann P.Schnrock R.Kuse D.Braumann H.J.Illiger W.Fiedler M.deWitt K.D.Hossfeld H.J.Weh 祁明芳
• 机 构: Bone Marrow Transplantaion Unit, Universittskrankenhaus Eppendorf,D-20246 Hamburg, Germany,广州暨南大学医学
• 出 处: 德国医学
• 发表日期: 2000年01期
• 关键词: 预处理方案 异基因骨髓移植 急性髓系白血病 无病生存率 足叶乙甙 马利兰 慢性白血病 大剂量化疗 造血干细胞移植 粘膜炎

大剂量化疗和全身放疗(TBI)后,组织相合的同胞造血干细胞移植已用于急、慢性白血病的治疗。它对第一次完全缓解(CR1)的急性髓系白血病(AML)患者,长期无病生存率可达50%,而对复发的急性白血病患者,长期无病生存率约为10%～20%。异基因骨髓移植(allo-BMT)预处理方案有 TBI+化疗和单用化疗两种。BuCy 方案是由 Santos 和Tutschka 设计的单化疗的预处理方案,原方案马利兰

After high-dose chemotherapy and systemic radiotherapy (TBI), tissue-matched sibling hematopoietic stem cell transplantation has been used for the treatment of acute and chronic leukemia. Its long-term disease-free survival is 50% for patients with acute myeloid leukemia (AML) who have first complete response (CR1), and 10% to 20% for patients with recurrent acute leukemia . Allogeneic bone marrow transplantation (allo-BMT) pretreatment program with TBI + chemotherapy and chemotherapy alone. The BuCy program is a single-chemotherapy pre-treatment program designed by Santos and Tutschka. The original program,